Figure 5.

BR101801 inhibits tumor growth by decreasing both Mcl-1 and c-Myc levels in DLBCL cells. A. SU-DHL-6 and DOHH-2 cells were treated with serial concentrations of BR101801 for 24 h, followed by Western blot analysis with the indicated antibodies. B. In vivo validation of BR101801 using SU-DHL-6 and DOHH-2 cells xenograft models. When the tumor size reached 100 mm³, BR101801 was orally administered daily through oral gavage. C. Histological analysis of xenograft tumor tissue using hematoxylin and eosin (H&E) staining, immunohistochemical detection of Mcl-1, c-Myc, and cleaved caspase 3. Data are presented as the mean ± S.D. (*P < 0.05, **P < 0.01, and ***P < 0.001).